Novo Nordisk B A/S
Novo Nordisk B A/S
-1,30 %
340,50 DKK
-4,50
Kurs
340,50
Hög
345,40
Förändring
-1,30 %
Låg
340,35
Uppdaterad
2019-06-14
Öppen
342,15
Factsheet for Novo Nordisk B A/S
Company Profile
Description
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, as well as oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Key Stats
Website: http://www.novonordisk.com
Headquarter country: Denmark
Employees: 35 000
Market Cap (at close 14-06-2019): DKK 809B
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings 18,90 21,60 17,30 31,30 26,50
Forward Price/Earnings 17,90 20,20 16,20 25,60 23,00
Price/Free Cash Flow 23,00 21,90 16,80 33,80 26,40
Return on Assets 36,20 38,20 40,10 41,30 35,90
Return on Equity 76,00 80,20 82,20 79,90 63,90
Return on Invested Capital 73,80 78,60 81,10 78,30 63,10
Dividend


Dividend/Share:7,90
Ex. Dividend Date:2018-12-31
Trailing Dividend Yield:2,39
Payout Ratio:51,29
Date Currency Amount
2019-03-31 DKK 5,15
2018-09-30 DKK 3,00
2018-03-31 DKK 4,85
2017-09-30 DKK 3,00
2017-03-31 DKK 4,60
2016-09-30 DKK 3,00
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 111 831,00 111 696,00 111 780,00 107 927,00 88 806,00
Gross Profit 94,21 94,06 94,60 91,74 74,24
Gross Margin % 84,25% 84,21% 84,63% 85,00% 83,60%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA 53 295,00 51 952,00 51 056,00 46 509,00 37 570,00
Net income 38 628,00 38 130,00 37 925,00 34 860,00 26 481,00
Basic Earnings Per Share 15,96 15,42 14,99 13,56 10,10
Operating Income 47,25 48,97 48,43 49,44 34,49
Operating Margin % 42,25% 43,84% 43,33% 45,81% 38,84%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow 44 616,00 41 168,00 48 314,00 38 287,00 31 692,00
Capital Expenditures -12 410,00 -8 648,00 -8 267,00 -6 406,00 -4 335,00
Free Cash Flow 32 206,00 32 520,00 40 047,00 31 881,00 27 357,00
Balance Sheet

Assets 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Current Assets 59 067,00 60 080,00 59 766,00 55 140,00 46 293,00 42 058,00
Long Term Assets 51 702,00 42 275,00 37 773,00 36 659,00 30 769,00 28 279,00
Total Assets 110 769,00 102 355,00 97 539,00 91 799,00 77 062,00 70 337,00
Liabilities 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Total Current Liabilities 54 164,00 47 056,00 47 436,00 40 873,00 33 689,00 24 225,00
Long Term Liabilities 4 834,00 3 957,00
Total Liabilities 52 270,00 44 830,00
Equity 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Retained Earnings 53 406,00 48 977,00 46 111,00 46 816,00 41 277,00 41 137,00
Treasury Stock 11,00 11,00 9,00 10,00 11,00 21,00
Total Stockholder Equity 51 839,00 49 815,00 45 269,00 46 969,00 40 294,00 42 569,00
Net Tangible Assets 46 694,00 46 490,00 42 555,00 44 811,00 38 916,00 40 954,00